Clinical trials: Rare Cancers, open to volunteers
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
- Conditions
- Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST), Adrenocortical Tumor
- Trial name
- PARTNER (NCT07072143)
- Where
- Italy
- Volunteers
- 6,250 people
- Sponsor
- Azienda Ospedaliera di Padova
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and…
- Trial name
- REZILIENT2 (NCT05967689)
- Testing
- TAS6417, CYP Cocktail, Transporter Cocktail
- Where
- 80 sites in United States, Australia and 10 more
- Volunteers
- 220 people
- Sponsor
- Taiho Oncology, Inc.
Lung Cancer (NSCLC)
Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations
This study evaluates the effectiveness and safety of targeted therapy given before and after surgery in patients with resectable or potentially resectable stage III non-small cell lung cancer with selected genetic alterations.
- Trial name
- NCT07829744
- Testing
- Surgical Resection
- Volunteers
- 190 people
- Sponsor
- Shanghai Zhongshan Hospital
Cancer, NGS
Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing.
- Conditions
- Cancer, NGS, Tumor, RARE DISEASE
- Trial name
- SONCO (NCT07147465)
- Where
- 3 sites in France
- Volunteers
- 3,149 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myasthenia Gravis
Integrating Art Therapy and Adapted Physical Activity: Toward Improved Quality of Life in Patients With Myasthenia Gravis
Myasthenia Gravis (MG) is a rare neuromuscular disease characterized by fluctuating muscle weakness and excessive fatigability. Although medical treatments have improved, MG continues to significantly impact patients' physical…
- Trial name
- APART-MG (NCT07125105)
- Testing
- Adapted Physical Activity Only, Adapted Physical Activity + Art Therapy
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Universite du Littoral Cote d'Opale
Non-small Cell Lung Cancer
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X…
- Trial name
- NCT05168566
- Testing
- Sutetinib Maleate Capsule
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 128 people
- Sponsor
- Teligene US
Head Neck Tumors, Neuroendocrine Tumors
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV rare cancers (In…
- Conditions
- Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma, Rare Cancer
- Trial name
- RaC-Ad (NCT04166006)
- Testing
- Autologous DC vaccine, Interleukin-2
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor
Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
The purpose of this study is to assess the efficacy and safety of abemaciclib and letrozole for treatment of estrogen receptor-positive rare ovarian cancer.
- Trial name
- ALEPRO (NCT05872204)
- Testing
- Abemaciclib, Letrozole
- Where
- 12 sites in Belgium, France and 1 more
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Rare Cancer
Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers
Rare cancers, defined by an incidence of fewer than 6 cases per 100,000 persons per year, constitute nearly 25% of adult malignancies.
- Trial name
- RATIONALE (NCT06855134)
- Where
- 16 sites in Germany
- Volunteers
- 946 people
- Sponsor
- German Cancer Research Center
Melanoma, Non Small Cell Lung Cancer
Dabrafenib and/or Trametinib Rollover Study
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
- Trial name
- NCT03340506
- Testing
- dabrafenib, trametinib
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Hematologic Malignancy
Solving Riddles Through Sequencing
During the last decades hematologists have excelled at improving and refining the classification, diagnosis, and thus ultimately the therapeutic decision-making process for their patients.
- Conditions
- Leukemia, Hematologic Malignancy, Rare Diseases, Refractory Leukemia
- Trial name
- SIRIUS (NCT05046444)
- Testing
- Next Generation Sequencing
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Munich Leukemia Laboratory
Rare Tumor
PLATFORM Study of Precision Medicine for Rare Tumors
A Phase II, open label, non-randomized, multiple-arm, single-center clinical trial in patients with advanced rare solid tumors who failed to standard treatment.
- Trial name
- NCT04423185
- Testing
- Almonertinib 110 MG, Dacomitinib 45 MG, Alectinib 150 MG
- Where
- China
- Volunteers
- 770 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Prader-Willi Syndrome, PWS-like Syndrome
GROWing Up With Rare GENEtic Syndromes
Introduction Rare complex syndromes Patients with complex genetic syndromes, by definition, have combined medical problems affecting multiple organ systems, and intellectual disability is often part of the syndrome.
- Conditions
- Prader-Willi Syndrome, PWS-like Syndrome, Silver Russel Syndrome, Congenital Hypopituitarism
- Trial name
- GROW UR GENES (NCT04463316)
- Testing
- Retrospective file studies
- Where
- Netherlands
- Volunteers
- 600 people
- Sponsor
- dr. Laura C. G. de Graaff-Herder
Embryonal Tumor
Rare Embryonal Tumors of the Central Nervous System: International Registry
Central nervous system (CNS) tumors are the most common solid malignancies among children. Although some types of CNS tumors like medulloblastomas and low-grade gliomas are widespread and well-studied, there is a huge number of…
- Trial name
- NCT05711992
- Where
- 11 sites in Armenia, Canada and 7 more
- Volunteers
- 300 people
- Sponsor
- Immune Oncology Research Institute
All Tumor Types
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer…
- Trial name
- SPECTA (NCT02834884)
- Testing
- RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen
- Where
- 136 sites in Austria, Belgium and 18 more
- Volunteers
- 4,975 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Background: Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough people to conduct large trials for new treatments.
- Conditions
- Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder, Squamous Cell Carcinoma of the Urinary Tract
- Trial name
- NCT06161532
- Testing
- Sacituzumab govitecan, Atezolizumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (1 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a…
- Trial name
- NCT05868629
- Testing
- Non-investigational
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Inherited Hematological Diseases, Rare Diseases
Longitudinal Studies of Patient With FPDMM
Background: Genes tell the body and its cells how to work. Familial platelet disease (FPD) or FPD with associated malignancies (FPDMM) is caused by a variant in the gene RUNX1.
- Conditions
- Inherited Hematological Diseases, Rare Diseases, FPDMM
- Trial name
- NCT03854318
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Gynecologic Cancer, Skin Cancer
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers.
- Conditions
- Gynecologic Cancer, Skin Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- OligoRARE (NCT04498767)
- Testing
- Stereotactic body radiotherapy, Palliative RT
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Chordoma
Children and Adults With Chordoma
Background: Chordoma is a rare type of bone cancer. It occurs in the skull base or spine. Researchers want to study people with chordoma in different ways.
- Trial name
- NCT03910465
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)